ABBN.SW: $85.78 ▼ -0.32 (-0.37%)ASML.AS: $1,568.00 ▲ 7.20 (0.46%)ENR.DE: $161.14 ▼ -1.36 (-0.84%)GLEN.L: $537.10 ▲ 1.80 (0.34%)IFX.DE: $81.30 ▲ 0.74 (0.92%)NOKIA.HE: $12.18 ▲ 0.18 (1.46%)RIO.L: $7,296.00 ▲ 32.00 (0.44%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Avenue Therapeutics, Inc.

ATXI - NASDAQ

Identifiants & Marche

Ticker ATXI
ISIN US05360L3042
CIK 0001644963
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.